GO
Loading...

Pharmaceuticals

More

  • TOKYO, Aug 18- Japan's Nikkei ended flat on Monday in thin trade as geopolitical tensions dulled risk appetite, but Chugai Pharmaceutical jumped on a media report that Roche Holding AG's may be close to sealing a deal to take full ownership of the Japanese drugmaker. The Nikkei was flat at 15,322.60 in choppy trade.

  • WASHINGTON, August 18- Establishing a tax domicile abroad to avoid U.S. taxes is a hot strategy in corporate America, but many companies that have done such "inversion" deals have failed to produce above-average returns for investors, a Reuters analysis has found.

  • TOKYO, Aug 18- Japan's Nikkei was choppy on Monday morning as geopolitical tensions checked risk appetite, but Chugai Pharmaceutical jumped on a media report that Roche Holding AG's may be close to sealing a deal to gain full ownership of the Japanese drugmaker.

  • LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.

  • NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.

  • Alabama high court upholds generic drug decision Friday, 15 Aug 2014 | 3:23 PM ET

    MONTGOMERY, Ala.— Brand-name drug makers can be held liable for warnings on a generic medication even if it was produced by another company, the Alabama Supreme Court ruled Friday, standing by an earlier decision that business leaders viewed as a defeat.

  • Is climate change key to the spread of Ebola? Friday, 15 Aug 2014 | 5:56 AM ET
    Women washing along the Niger River near Babila, Guinea.

    Ebola outbreaks may become more frequent because of climate change, scientists warn, as the deadly disease ravages West Africa.

  • BOSTON, Aug 14- Billionaire investor William Ackman, who often says he is flattered when others follow him into a stock he likes, was joined by several prominent hedge funds that made new bets on takeover target Allergan Inc during the second quarter.

  • Aug 14- Pershing Square Capital Management LP, the hedge fund firm run by William Ackman, has sued the U.S. government, claiming that its stripping of Fannie Mae's and Freddie Mac's profit illegally short changes investors in the mortgage companies' common stock.

  • SAN FRANCISCO, Aug 14- A group of ex-gaming industry executives say they can use their design chops to solve a major health challenge: Sick patients neglecting to take their medication and costing employers and insurance providers billions of dollars.

  • Aug 14- U.S. securities regulators are looking at the hostile takeover bid made by billionaire investor William Ackman and Valeant Pharmaceuticals for Botox maker Allergan Inc, a person familiar with the matter said on Thursday.

  • NEW YORK, Aug 14- A federal judge rejected billionaire investor Steven A. Cohen's bid to dismiss lawsuits by Elan Corp and Wyeth shareholders who claimed they lost money because his firm SAC Capital Advisors LP conducted insider trading in the drugmakers' stocks.

  • NEW YORK, Aug 14- A federal judge narrowed but refused to dismiss lawsuits by former Elan Corp and Wyeth shareholders seeking to recoup losses from billionaire investor Steven A. Cohen and his firm SAC Capital Advisors LP over insider trading in the drugmakers' stocks.

  • Yaron Werber, Citi Investment Research, shares his thoughts on news Kyprolis failed to meet its primary endpoint of improving overall survival for patients with multiple myeloma.

  • NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.

  • Investors should expect more from Merck: Pro     Wednesday, 13 Aug 2014 | 11:40 AM ET

    Raghuram Selvaraju, head of healthcare equity research at Aegis Capital, says "German Merck's" second quarter was "solid and respectable" but that its biopharmaceutical business is its weak spot.

  • UPDATE 2-Rigel eye drug fails mid-stage study, shares fall Wednesday, 13 Aug 2014 | 10:48 AM ET

    Aug 13- Rigel Pharmaceuticals Inc said it would stop testing its drug for some patients with dry eye disease after the treatment failed a mid-stage study. British drugmaker AstraZeneca Plc scrapped its licensing deal for Rigel's rheumatoid arthritis treatment in June 2013.

  • Aug 13- Rigel Pharmaceuticals Inc said its experimental drug failed to meet the main goal in a mid-stage study in patients with dry eye disease, sending its shares down 10.7 percent in premarket trading. British drugmaker AstraZeneca stopped developing Rigel's rheumatoid arthritis treatment in June 2013.

  • Cramer's Mad Dash: Intercept soars     Tuesday, 12 Aug 2014 | 9:28 AM ET

    Jim Cramer explains what to watch ahead of the open, including Intercept Pharmaceuticals.

  • Clinical trial to start soon on GSK Ebola vaccine Monday, 11 Aug 2014 | 1:17 AM ET

    A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to GlaxoSmithKline.